Treatment of Papillary Thyroid Cancer at Low Estimated Risk of Recurrence (T1a–T2, N0, Intrathyroidal)
Clinical Scenario
This protocol addresses papillary thyroid carcinoma at low estimated risk of recurrence: tumours staged T1a, T1b, or T2 that are confined within the thyroid (intrathyroidal), with no locoregional lymph node metastases (N0). In this presentation, the choice and extent of initial surgery are central to management.
Surgical Approach (Partial Overview)
For this low-risk presentation, an operation targeting the affected thyroid lobe is among the surgical strategies considered. Whether a more extended procedure is required depends on criteria detailed in the full protocol.
Complete surgical decision criteria, the role of neck dissection, and individualized selection factors are available in the full protocol.
Treatment Goals
An excellent response to therapy is the target, assessed 6–18 months after treatment: negative imaging, undetectable anti-thyroglobulin antibodies, and serum thyroglobulin below defined thresholds. The full protocol specifies the precise thresholds and follow-up assessment framework.
References
DOI: 10.1093/annonc/mdz400
- Two large database studies on surgical management strategies found that, for selected low-risk tumours (T1a–T1b–T2, N0), lobectomy alone does not reduce OS.
- Lobectomy (instead of total thyroidectomy) may be proposed for selected low-risk (T1a–T1b–T2, N0) tumours.
- The use of prophylactic central neck dissection for low-risk tumours (T1b–T2, N0) varies from centre to centre.
- All patients with DTC should have neck US and serum Tg and TgAb assays 6–18 months after primary treatment.
- In patients treated with total thyroidectomy plus RAI remnant ablation, stimulated serum Tg levels <1 ng/ml are highly predictive of an excellent response to therapy, and subsequent stimulated Tg assays are unnecessary.
View source ↗